How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
The complexities of Psoriatic Arthritis (PsA) demand a tailored approach to treatment. With the diverse patient responses to medications, a one-size-fits-all strategy is not viable. Enter Baysient’s groundbreaking software applications, iDose® and T3®, which are redefining the therapeutic drug monitoring process for PsA. The Challenge…